A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)

A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)

Objectives: To develop a mutation-based radiomics signature to predict response to imatinib in Gastrointestinal Stromal Tumors (GISTs). Methods: Eighty-two patients with GIST were enrolled in this retrospective study, including 52 patients from one center that were used to develop the model, and 30...

Full description

Bibliographic Details
Main Authors: Giovanni Cappello, Valentina Giannini, Roberto Cannella, Emanuele Tabone, Ilaria Ambrosini, Francesca Molea, Nicolò Damiani, Ilenia Landolfi, Giovanni Serra, Giorgia Porrello, Cecilia Gozzo, Lorena Incorvaia, Giuseppe Badalamenti, Giovanni Grignani, Alessandra Merlini, Lorenzo D’Ambrosio, Tommaso Vincenzo Bartolotta, Daniele Regge
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:European Journal of Radiology Open
Subjects:
Artificial intelligence
Radiomics
GIST
Mutational status
Response to therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S235204772300031X

Similar Items

Similar Items